ABclonal

ABclonal, established in 2011, is a prominent manufacturer specializing in biology research reagents and services. Headquartered in Woburn, Massachusetts, the company focuses on the life science research sector, providing a comprehensive suite of products including antibodies, proteins, and ELISA kits. Its product catalog encompasses critical research tools such as monoclonal antibodies, peptides, and cell-based assays, supporting advancements in diagnostics and life science research. ABclonal's commitment to innovation is evident in its proprietary technologies and diverse product offerings, serving researchers globally.

Operating with a significant workforce of 500 - 1,000 employees, ABclonal maintains a singular primary location, indicating a centralized operational structure. The company's extensive product range supports various research applications, from fundamental biological studies to applied diagnostics. Its focus on quality and scientific rigor positions it as a key supplier in the competitive biotechnology landscape. For insights into the people driving its innovation, you can Meet ABclonal's team. The company's strategic growth is supported by its dedicated team and robust product development pipeline.

Financially, ABclonal reported a revenue of $28.6M. The company has secured substantial funding, including a Series C round of $92.9M in February 2021, with notable investors like Sequoia Capital China and LYFE Capital. This financial backing underscores its market potential and expansion capabilities within the Test & Measurement Equipment and Manufacturing industries. ABclonal competes with established players like Sino Biological and Elabscience, leveraging its specialized reagents and services to capture market share. Investors and stakeholders can Explore financial highlights for detailed performance metrics and funding history.